Awakesoul Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 59.76%
- Profit Growth -64.72%
- Ebitda -35.18%
- Net Worth -242.55%
- Total Assets -5.68%
About Awakesoul Pharmaceutical
Awakesoul Pharmaceutical Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 June 2016 (Eight years and eight months 22 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Surinder Suri and Rajendra Oberoi serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304DL2016PTC300846
- Company No.
300846
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jun 2016
- Date of AGM
29 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Awakesoul Pharmaceutical Private Limited offer?
Awakesoul Pharmaceutical Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Gastrointestinal Drugs.
Who are the key members and board of directors at Awakesoul Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surinder Suri  | Director | 03-Jun-2016 | Current |
| Rajendra Oberoi | Director | 03-Jun-2016 | Current |
Financial Performance of Awakesoul Pharmaceutical.
Awakesoul Pharmaceutical Private Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 59.76% increase. The company also saw a substantial fall in profitability, with a 64.72% decrease in profit. The company's net worth observed a substantial decline by a decrease of 242.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Awakesoul Pharmaceutical?
In 2018, Awakesoul Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Awakesoul Pharmaceutical?
Unlock and access historical data on people associated with Awakesoul Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Awakesoul Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Awakesoul Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
